LOTRONEX Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Lotronex, and when can generic versions of Lotronex launch?
Lotronex is a drug marketed by Sebela Ireland Ltd and is included in one NDA.
The generic ingredient in LOTRONEX is alosetron hydrochloride. There are three drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the alosetron hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Lotronex
A generic version of LOTRONEX was approved as alosetron hydrochloride by AMNEAL PHARMS on December 22nd, 2016.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LOTRONEX?
- What are the global sales for LOTRONEX?
- What is Average Wholesale Price for LOTRONEX?
Summary for LOTRONEX
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 158 |
Patent Applications: | 1,531 |
Drug Prices: | Drug price information for LOTRONEX |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for LOTRONEX |
What excipients (inactive ingredients) are in LOTRONEX? | LOTRONEX excipients list |
DailyMed Link: | LOTRONEX at DailyMed |
Pharmacology for LOTRONEX
Drug Class | Serotonin-3 Receptor Antagonist |
Mechanism of Action | Serotonin 3 Receptor Antagonists |
Paragraph IV (Patent) Challenges for LOTRONEX
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
LOTRONEX | Tablets | alosetron hydrochloride | 0.5 mg and 1 mg | 021107 | 1 | 2010-12-02 |
US Patents and Regulatory Information for LOTRONEX
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sebela Ireland Ltd | LOTRONEX | alosetron hydrochloride | TABLET;ORAL | 021107-002 | Dec 23, 2003 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Sebela Ireland Ltd | LOTRONEX | alosetron hydrochloride | TABLET;ORAL | 021107-001 | Feb 9, 2000 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for LOTRONEX
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Sebela Ireland Ltd | LOTRONEX | alosetron hydrochloride | TABLET;ORAL | 021107-002 | Dec 23, 2003 | ⤷ Sign Up | ⤷ Sign Up |
Sebela Ireland Ltd | LOTRONEX | alosetron hydrochloride | TABLET;ORAL | 021107-001 | Feb 9, 2000 | ⤷ Sign Up | ⤷ Sign Up |
Sebela Ireland Ltd | LOTRONEX | alosetron hydrochloride | TABLET;ORAL | 021107-001 | Feb 9, 2000 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for LOTRONEX
See the table below for patents covering LOTRONEX around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Peru | 120299 | USO DE UN ANTAGONISTA DE 5-HIDROXITRIPTAMINA | ⤷ Sign Up |
Tunisia | SN98179 | MEDICAMENTS | ⤷ Sign Up |
Japan | 2001518495 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |